Status:
RECRUITING
Early Discontinuation of Empirical Antifungal Therapy and Biomarkers
Lead Sponsor:
University Hospital, Lille
Conditions:
Invasive Candidiasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Empirical antifungal therapy (EAT) is frequently prescribed to septic critically ill patients with risk factors for invasive Candida infections (ICI). However, among patients without subsequent proven...
Detailed Description
Patients requiring EAT will be randomly assigned to: * intervention group: a strategy in which EAT duration is determined by (1,3)-B-Dglucan and mannan serum assays, performed on day 0 (day of EAT in...
Eligibility Criteria
Inclusion Criteria:
- Patient older than 18 years
- Who require EAT for the first time in the ICU (this treatment is prescribed based on the presence of risk factors and clinical suspicion of ICI)
- With an expected ICU length of stay of at least 6 days after EAT initiation
- Informed written consent
Exclusion Criteria:
- Neutropenia (neutrophil count <500 cells /µL)
- Active malignant hemopathy
- Bone marrow transplantation in the last 6 months
- Polyvalent immunoglobulins in the past months
- Documented ICI in the past 3 months
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
June 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
194 Patients enrolled
Trial Details
Trial ID
NCT03538912
Start Date
June 6 2018
End Date
June 1 2025
Last Update
May 16 2024
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
CH ARRAS
Arras, France
2
CH de DOUAI
Douai, France
3
CH Dunkerque
Dunkirk, France
4
Centre Hospitalier Dr Schaffner
Lens, France